The DOI matches its Crossref record; 137 of the 137 references it cites were found in a registry or an index.
Clinical implications of PTEN loss in prostate cancer
Open accessAbstract
Genomic aberrations of the PTEN tumour suppressor gene are among the most common in prostate cancer. Inactivation of PTEN by deletion or mutation is identified in ∼20% of primary prostate tumour samples at radical prostatectomy and in as many as 50% of castration-resistant tumours. Loss of phosphatase and tensin homologue (PTEN) function leads to activation of the PI3K–AKT (phosphoinositide 3-kinase–RAC-alpha serine/threonine-protein kinase) pathway and is strongly associated with adverse oncological outcomes, making PTEN a potentially useful genomic marker to distinguish indolent from aggressive disease in patients with clinically localized tumours. At the other end of the disease spectrum, therapeutic compounds targeting nodes in the PI3K–AKT–mTOR (mechanistic target of rapamycin) signalling pathway are being tested in clinical trials for patients with metastatic castration-resistant prostate cancer. Knowledge of PTEN status might be helpful to identify patients who are more likely to benefit from these therapies. To enable the use of PTEN status as a prognostic and predictive biomarker, analytically validated assays have been developed for reliable and reproducible detection of PTEN loss in tumour tissue and in blood liquid biopsies. The use of clinical-grade assays in tumour tissue has shown a robust correlation between loss of PTEN and its protein as well as a strong association between PTEN loss and adverse pathological features and oncological outcomes. In advanced disease, assessing PTEN status in liquid biopsies shows promise in predicting response to targeted therapy. Finally, studies have shown that PTEN might have additional functions that are independent of the PI3K–AKT pathway, including those affecting tumour growth through modulation of the immune response and tumour microenvironment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
Integrative Genomic Profiling of Human Prostate Cancer
Taylor, B. S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., Cerami, E., Reva, B., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.026 · Cited by 3,701
Self-citationIntegrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
Self-citationEpstein, J. I., Egevad, L., Amin, M. B., Delahunt, B., Srigley, J. R., & Humphrey, P. A. (2016) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000530 · Cited by 3,236
The Molecular Taxonomy of Primary Prostate Cancer
Abeshouse, A., Ahn, J., Akbani, R., Ally, A., Amin, S., Andry, C. D., Annala, M., Aprikian, A., Armenia, J., Arora, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.10.025 · Cited by 3,110
Maehama, T., & Dixon, J. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13375 · Cited by 3,104
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
The PI3K Pathway in Human Disease
Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017) · Cell · doi:10.1016/j.cell.2017.07.029 · Cited by 2,749
Steck, P. A., Pershouse, M. A., Jasser, S. A., Yung, W. K. A., Lin, H., Ligon, A. H., Langford, L. A., Baumgard, M. L., Hattier, T., Davis, T., et al. (1997) · Nature Genetics · doi:10.1038/ng0497-356 · Cited by 2,741
The mutational landscape of lethal castration-resistant prostate cancer
Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., et al. (2012) · Nature · doi:10.1038/nature11125 · Cited by 2,517
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506859 · Cited by 2,185
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis
Chen, Z., Trotman, L. C., Shaffer, D., Lin, H.-K., Dotan, Z. A., Niki, M., Koutcher, J. A., Scher, H. I., Ludwig, T., Gerald, W., et al. (2005) · Nature · doi:10.1038/nature03918 · Cited by 1,993
Self-citationThe functions and regulation of the PTEN tumour suppressor
Song, M. S., Salmena, L., & Pandolfi, P. P. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3330 · Cited by 1,926
Inflammation in prostate carcinogenesis
De Marzo, A. M., Platz, E. A., Sutcliffe, S., Xu, J., Grönberg, H., Drake, C. G., Nakai, Y., Isaacs, W. B., & Nelson, W. G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2090 · Cited by 1,621
Self-citationExome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer
Barbieri, C. E., Baca, S. C., Lawrence, M. S., Demichelis, F., Blattner, M., Theurillat, J.-P., White, T. A., Stojanov, P., Van Allen, E., Stransky, N., et al. (2012) · Nature Genetics · doi:10.1038/ng.2279 · Cited by 1,558
Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Peng, W., Chen, J. Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M. T., Xu, C., McKenzie, J. A., Zhang, C., Liang, X., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0283 · Cited by 1,539
Pten is essential for embryonic development and tumour suppression
Cristofano, A. D., Pesce, B., Cordon-Cardo, C., & Pandolfi, P. P. (1998) · Nature Genetics · doi:10.1038/1235 · Cited by 1,516
The evolutionary history of lethal metastatic prostate cancer
ICGC Prostate UK Group, Gundem, G., Van Loo, P., Kremeyer, B., Alexandrov, L. B., Tubio, J. M. C., Papaemmanuil, E., Brewer, D. S., Kallio, H. M. L., Högnäs, G., et al. (2015) · Nature · doi:10.1038/nature14347 · Cited by 1,388
A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score
Epstein, J. I., Zelefsky, M. J., Sjoberg, D. D., Nelson, J. B., Egevad, L., Magi-Galluzzi, C., Vickers, A. J., Parwani, A. V., Reuter, V. E., Fine, S. W., et al. (2016) · European Urology · doi:10.1016/j.eururo.2015.06.046 · Cited by 1,374
The genomic complexity of primary human prostate cancer
Berger, M. F., Lawrence, M. S., Demichelis, F., Drier, Y., Cibulskis, K., Sivachenko, A. Y., Sboner, A., Esgueva, R., Pflueger, D., Sougnez, C., et al. (2011) · Nature · doi:10.1038/nature09744 · Cited by 1,234
Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN
Tamura, M., Gu, J., Matsumoto, K., Aota, S.-I., Parsons, R., & Yamada, K. M. (1998) · Science · doi:10.1126/science.280.5369.1614 · Cited by 1,215
Carver, B. S., Chapinski, C., Wongvipat, J., Hieronymus, H., Chen, Y., Chandarlapaty, S., Arora, V. K., Le, C., Koutcher, J., Scher, H., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.008 · Cited by 1,198
Self-citationWang, S., Gao, J., Lei, Q., Rozengurt, N., Pritchard, C., Jiao, J., Thomas, G. V., Li, G., Roy-Burman, P., Nelson, P. S., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00215-0 · Cited by 1,109
Ku, S. Y., Rosario, S., Wang, Y., Mu, P., Seshadri, M., Goodrich, Z. W., Goodrich, M. M., Labbé, D. P., Gomez, E. C., Wang, J., et al. (2017) · Science · doi:10.1126/science.aah4199 · Cited by 1,089
Tenets of PTEN Tumor Suppression
Salmena, L., Carracedo, A., & Pandolfi, P. P. (2008) · Cell · doi:10.1016/j.cell.2008.04.013 · Cited by 1,034
Coding-Independent Regulation of the Tumor Suppressor PTEN by Competing Endogenous mRNAs
Tay, Y., Kats, L., Salmena, L., Weiss, D., Tan, S. M., Ala, U., Karreth, F., Poliseno, L., Provero, P., Di Cunto, F., et al. (2011) · Cell · doi:10.1016/j.cell.2011.09.029 · Cited by 1,019
Essential role for nuclear PTEN in maintaining chromosomal integrity
Shen, W. H., Balajee, A. S., Wang, J., Wu, H., Eng, C., Pandolfi, P. P., & Yin, Y. (2007) · Cell · doi:10.1016/j.cell.2006.11.042 · Cited by 979
Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems
Podsypanina, K., Ellenson, L. H., Nemes, A., Gu, J., Tamura, M., Yamada, K. M., Cordon-Cardo, C., Catoretti, G., Fisher, P. E., & Parsons, R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.4.1563 · Cited by 946
Frequent inactivation of PTEN/MMAC1 in primary prostate cancer.
Cairns, P., Okami, K., Halachmi, S., Halachmi, N., Esteller, M., Herman, J. G., Jen, J., Isaacs, W. B., Bova, G. S., & Sidransky, D. (1997) · PubMed · Cited by 700
Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis
Jia, S., Liu, Z., Zhang, S., Liu, P., Zhang, L., Lee, S. H., Zhang, J., Signoretti, S., Loda, M., Roberts, T. M., et al. (2008) · Nature · doi:10.1038/nature07091 · Cited by 688
Pten Dose Dictates Cancer Progression in the Prostate
Trotman, L. C., Niki, M., Dotan, Z. A., Koutcher, J. A., Di Cristofano, A., Xiao, A., Khoo, A. S., Roy-Burman, P., Greenberg, N. M., Dyke, T. V., et al. (2003) · PLoS Biology · doi:10.1371/journal.pbio.0000059 · Cited by 676
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate
Carver, B. S., Tran, J., Gopalan, A., Chen, Z., Shaikh, S., Carracedo, A., Alimonti, A., Nardella, C., Varmeh, S., Scardino, P. T., et al. (2009) · Nature Genetics · doi:10.1038/ng.370 · Cited by 659
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer
Liu, W., Laitinen, S., Khan, S., Vihinen, M., Kowalski, J., Yu, G., Chen, L., Ewing, C. M., Eisenberger, M. A., Carducci, M. A., et al. (2009) · Nature Medicine · doi:10.1038/nm.1944 · Cited by 654
Whang, Y. E., Wu, X., Suzuki, H., Reiter, R. E., Tran, C., Vessella, R. L., Said, J. W., Isaacs, W. B., & Sawyers, C. L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.9.5246 · Cited by 639
Tosoian, J. J., Mamawala, M., Epstein, J. I., Landis, P., Wolf, S., Trock, B. J., & Carter, H. B. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.5764 · Cited by 555
Attard, G., Swennenhuis, J. F., Olmos, D., Reid, A. H. M., Vickers, E., A'Hern, R., Levink, R., Coumans, F., Moreira, J., Riisnaes, R., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3667 · Cited by 533
Cell Autonomous Role of PTEN in Regulating Castration-Resistant Prostate Cancer Growth
Mulholland, D. J., Tran, L. M., Li, Y., Cai, H., Morim, A., Wang, S., Plaisier, S., Garraway, I. P., Huang, J., Graeber, T. G., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.05.006 · Cited by 516
Zhang, S., Huang, W.-C., Li, P., Guo, H., Poh, S.-B., Brady, S. W., Xiong, Y., Tseng, L.-M., Li, S.-H., Ding, Z., et al. (2011) · Nature Medicine · doi:10.1038/nm.2309 · Cited by 515
Tracking the clonal origin of lethal prostate cancer
Haffner, M. C., Mosbruger, T., Esopi, D. M., Fedor, H., Heaphy, C. M., Walker, D. A., Adejola, N., Gürel, M., Hicks, J., Meeker, A. K., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70354 · Cited by 497
Self-citationCooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis
King, J. C., Xu, J., Wongvipat, J., Hieronymus, H., Carver, B. S., Leung, D. H., Taylor, B. S., Sander, C., Cardiff, R. D., Couto, S. S., et al. (2009) · Nature Genetics · doi:10.1038/ng.371 · Cited by 477
Beltran, H., Yelensky, R., Frampton, G. M., Park, K., Downing, S. R., MacDonald, T. Y., Jarosz, M., Lipson, D., Tagawa, S. T., Nanus, D. M., et al. (2013) · European Urology · doi:10.1016/j.eururo.2012.08.053 · Cited by 454
Suzuki, H., Freije, D., Nusskern, D. R., Okami, K., Cairns, P., Sidransky, D., Isaacs, W. B., & Bova, G. S. (1998) · PubMed · Cited by 452
Toso, A., Revandkar, A., Di Mitri, D., Guccini, I., Proietti, M., Sarti, M., Pinton, S., Zhang, J., Kalathur, M., Civenni, G., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.08.044 · Cited by 418
High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice.
Stambolic, V., Tsao, M., MacPherson, D. P., Suzuki, A., Chapman, W. B., & Mak, T. W. (2000) · PubMed · Cited by 414
Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer
Wyatt, A. W., Annala, M., Aggarwal, R., Beja, K., Feng, F., Youngren, J., Foye, A., Lloyd, P., Nykter, M., Beer, T. M., et al. (2017) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx118 · Cited by 412
Poliseno, L., Salmena, L., Riccardi, L., Fornari, A., Song, M. S., Hobbs, R. M., Sportoletti, P., Varmeh, S., Egia, A., Fedele, G., et al. (2010) · Science Signaling · doi:10.1126/scisignal.2000594 · Cited by 410
Nuclear PTEN controls DNA repair and sensitivity to genotoxic stress
Bassi, C., Ho, J., Srikumar, T., Dowling, R. J. O., Gorrini, C., Miller, S. J., Mak, T. W., Neel, B. G., Raught, B., & Stambolic, V. (2013) · Science · doi:10.1126/science.1236188 · Cited by 403
Wyatt, A. W., Azad, A. A., Volik, S. V., Annala, M., Beja, K., McConeghy, B., Haegert, A., Warner, E. W., Mo, F., Brahmbhatt, S., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0494 · Cited by 373
Lotan, T. L., Gurel, B., Sutcliffe, S., Esopi, D., Liu, W., Xu, J., Hicks, J. L., Park, B. H., Humphreys, E., Partin, A. W., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1244 · Cited by 348
Self-citationRb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma
Tan, H.-L., Sood, A., Rahimi, H. A., Wang, W., Gupta, N., Hicks, J., Mosier, S., Gocke, C. D., Epstein, J. I., Netto, G. J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1982 · Cited by 346
Self-citationKrohn, A., Diedler, T., Burkhardt, L., Mayer, P.-S., De Silva, C., Meyer-Kornblum, M., Kötschau, D., Tennstedt, P., Huang, J., Gerhäuser, C., et al. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.04.026 · Cited by 324
A Secreted PTEN Phosphatase That Enters Cells to Alter Signaling and Survival
Hopkins, B. D., Fine, B., Steinbach, N., Dendy, M., Rapp, Z., Shaw, J., Pappas, K., Yu, J. S., Hodakoski, C., Mense, S., et al. (2013) · Science · doi:10.1126/science.1234907 · Cited by 320
Pettersson, A., Graff, R. E., Bauer, S. R., Pitt, M. J., Lis, R. T., Stack, E. C., Martin, N. E., Kunz, L., Penney, K. L., Ligon, A. H., et al. (2012) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-12-0042 · Cited by 319
Yoshimoto, M., Cunha, I. W., Coudry, R. A., Fonseca, F. P., Torres, C. H., Soares, F. A., & Squire, J. A. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603924 · Cited by 295
Self-citationAparicio, A. M., Shen, L., Tapia, E. L. N., Lu, J.-F., Chen, H.-C., Zhang, J., Wu, G., Wang, X., Troncoso, P., Corn, P., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1259 · Cited by 295
Chen, Y., Chi, P., Rockowitz, S., Iaquinta, P. J., Shamu, T., Shukla, S., Gao, D., Sirota, I., Carver, B. S., Wongvipat, J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3216 · Cited by 282
Self-citationYoshimoto, M., Joshua, A. M., Cunha, I. W., Coudry, R. A., Fonseca, F. P., Ludkovski, O., Zielenska, M., Soares, F. A., & Squire, J. A. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.96 · Cited by 279
Self-citationPI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance
Hsieh, A., & Edlind, M. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.122876 · Cited by 276
Ferraldeschi, R., Nava Rodrigues, D., Riisnaes, R., Miranda, S., Figueiredo, I., Rescigno, P., Ravi, P., Pezaro, C., Omlin, A., Lorente, D., et al. (2015) · European Urology · doi:10.1016/j.eururo.2014.10.027 · Cited by 268
Weng, L.-P. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.6.599 · Cited by 264
Gannon, P. O., Poisson, A. O., Delvoye, N., Lapointe, R., Mes-Masson, A.-M., & Saad, F. (2009) · Journal of Immunological Methods · doi:10.1016/j.jim.2009.06.004 · Cited by 261
on behalf of the Transatlantic Prostate Group, Reid, A. H. M., Attard, G., Ambroisine, L., Fisher, G., Kovacs, G., Brewer, D., Clark, J., Flohr, P., Edwards, S., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605554 · Cited by 250
Schwartz, S., Wongvipat, J., Trigwell, C. B., Hancox, U., Carver, B. S., Rodrik-Outmezguine, V., Will, M., Yellen, P., de Stanchina, E., Baselga, J., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.008 · Cited by 246
Self-citationTherapeutic Targeting of Cancers with Loss of PTEN Function
Dillon, L., & Miller, T. (2014) · Current Drug Targets · doi:10.2174/1389450114666140106100909 · Cited by 241
DNA Repair in Prostate Cancer: Biology and Clinical Implications
Mateo, J., Boysen, G., Barbieri, C. E., Bryant, H. E., Castro, E., Nelson, P. S., Olmos, D., Pritchard, C. C., Rubin, M. A., & de Bono, J. S. (2017) · European Urology · doi:10.1016/j.eururo.2016.08.037 · Cited by 239
Analysis of PTEN and the 10q23 region in primary prostate carcinomas
Feilotter, H. E., Nagai, M. A., Boag, A. H., Eng, C., & Mulligan, L. M. (1998) · Oncogene · doi:10.1038/sj.onc.1200205 · Cited by 230
Han, B., Mehra, R., Lonigro, R. J., Wang, L., Suleman, K., Menon, A., Palanisamy, N., Tomlins, S. A., Chinnaiyan, A. M., & Shah, R. B. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.69 · Cited by 227
Promoter methylation of the PTEN gene is a common molecular change in breast cancer
García, J. M., Silva, J., Peña, C., Garcia, V., Rodríguez, R., Cruz, M. A., Cantos, B., Provencio, M., España, P., & Bonilla, F. (2004) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20062 · Cited by 224
Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas.
Wang, S. I., Parsons, R. E., & Ittmann, M. (1998) · PubMed · Cited by 218
Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer
Zhao, D., Lu, X., Wang, G., Lan, Z., Liao, W., Li, J., Liang, X., Chen, J. R., Shah, S., Shang, X., et al. (2017) · Nature · doi:10.1038/nature21357 · Cited by 218
Sircar, K., Yoshimoto, M., Monzon, F. A., Koumakpayi, I. H., Katz, R. L., Khanna, A., Alvarez, K., Chen, G., Darnel, A. D., Aprikian, A. G., et al. (2009) · The Journal of Pathology · doi:10.1002/path.2559 · Cited by 208
Self-citationBlattner, M., Liu, D., Robinson, B. D., Huang, D., Poliakov, A., Gao, D., Nataraj, S., Deonarine, L. D., Augello, M. A., Sailer, V., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.004 · Cited by 204
The tumor suppressor PTEN has a critical role in antiviral innate immunity
Li, S., Zhu, M., Pan, R., Fang, T., Cao, Y.-Y., Chen, S., Zhao, X., Lei, C.-Q., Guo, L., Chen, Y., et al. (2016) · Nature Immunology · doi:10.1038/ni.3311 · Cited by 195
A prospective investigation of PTEN loss and ERG expression in lethal prostate cancer
Ahearn, T. U., Pettersson, A., Ebot, E. M., Gerke, T., Graff, R. E., Morais, C. L., Hicks, J. L., Wilson, K. M., Rider, J. R., Sesso, H. D., et al. (2015) · Journal of the National Cancer Institute · doi:10.1093/jnci/djv346 · Cited by 186
Self-citationImmune Infiltration and Prostate Cancer
Strasner, A., & Karin, M. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00128 · Cited by 184
Yoshimoto, M., Cutz, J.-C., Nuin, P. A. S., Joshua, A. M., Bayani, J., Evans, A. J., Zielenska, M., & Squire, J. A. (2006) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2006.04.003 · Cited by 181
Self-citationActive surveillance for prostate cancer: a narrative review of clinical guidelines
the Movember GAP3 consortium, Bruinsma, S. M., Bangma, C. H., Carroll, P. R., Leapman, M. S., Rannikko, A., Petrides, N., Weerakoon, M., Bokhorst, L. P., & Roobol, M. J. (2016) · Nature Reviews Urology · doi:10.1038/nrurol.2015.313 · Cited by 180
Jiao, J., Wang, S., Qiao, R., Vivanco, I., Watson, P. A., Sawyers, C. L., & Wu, H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4202 · Cited by 172
STAT3 regulated ARF expression suppresses prostate cancer metastasis
Pencik, J., Schlederer, M., Gruber, W., Unger, C., Walker, S. M., Chalaris, A., Marié, I. J., Hassler, M. R., Javaheri, T., Aksoy, O., et al. (2015) · Nature Communications · doi:10.1038/ncomms8736 · Cited by 170
Lindsay, Y. E., McCoull, D., Davidson, L., Leslie, N. R., Fairservice, A., Gray, A., Lucocq, J. M., & Downes, C. P. (2006) · Journal of Cell Science · doi:10.1242/jcs.000133 · Cited by 166
Evidence for Molecular Differences in Prostate Cancer between African American and Caucasian Men
Khani, F., Mosquera, J. M., Park, K., Blattner, M., O'Reilly, C., MacDonald, T. Y., Chen, Z., Srivastava, A., Tewari, A. K., Barbieri, C. E., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2265 · Cited by 164
Brito, M. B., Goulielmaki, E., & Papakonstanti, E. A. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00166 · Cited by 162
Lotan, T. L., Gümüşkaya, B., Rahimi, H. A., Hicks, J. L., Iwata, T., Robinson, B. D., Epstein, J. I., & Marzo, A. M. D. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.201 · Cited by 158
Self-citationNon-genomic loss of PTEN function in cancer: not in my genes
Leslie, N. R., & Foti, M. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.12.005 · Cited by 158
PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy
Lotan, T. L., Carvalho, F. L. F., Peskoe, S. B., Hicks, J. L., Good, J. L., Fedor, H. L., Humphreys, E. B., Han, M., Platz, E. A., Squire, J. A., et al. (2014) · Modern Pathology · doi:10.1038/modpathol.2014.85 · Cited by 152
Self-citationThomas, C., Lamoureux, F., Crafter, C., Davies, B. R., Beraldi, E., Fazli, L., Kim, S., Thaper, D., Gleave, M. E., & Zoubeidi, A. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0032 · Cited by 147
Is PTEN loss associated with clinical outcome measures in human prostate cancer?
McCall, P. J., Witton, C. J., Grimsley, S. J. S., Nielsen, K., & Edwards, J. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604680 · Cited by 145
Pten Inactivation and the Emergence of Androgen-Independent Prostate Cancer
Shen, M. M., & Abate-Shen, C. T. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1271 · Cited by 144
Loss of PTEN Is Associated with Aggressive Behavior in ERG-Positive Prostate Cancer
Leinonen, K. A., Saramäki, O. R., Furusato, B., Kimura, T., Takahashi, H., Egawa, S., Suzuki, H., Keiger, K., Hahm, S. H., Isaacs, W. B., et al. (2013) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-13-0333-t · Cited by 144
Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations
Huang, F. W., Mosquera, J. M., Garofalo, A., Oh, C., Baco, M. B., Amin‐Mansour, A., Rabasha, B., Bahl, S., Mullane, S. A., Robinson, B. D., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0960 · Cited by 142
Hubbard, G. K., Mutton, L. N., Khalili, M., McMullin, R. P., Hicks, J. L., Bianchi-Frias, D., Horn, L. A., Kulaç, İ., Moubarek, M. S., Nelson, P. S., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3280 · Cited by 136
Chaux, A., Peskoe, S. B., González-Roibón, N., Schultz, L., Albadine, R., Hicks, J. L., Marzo, A. M. D., Platz, E. A., & Netto, G. J. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.104 · Cited by 135
PTEN/MMAC1/TEP1 involvement in primary prostate cancers
Pesche, S., Latil, A., Muzeau, F., Cussenot, O., Fournier, G., Longy, M., Eng, C., & Lidereau, R. (1998) · Oncogene · doi:10.1038/sj.onc.1202081 · Cited by 131
PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer
Bismar, T. A., Yoshimoto, M., Vollmer, R. T., Duan, Q., Firszt, M., Corcos, J., & Squire, J. A. (2010) · British Journal of Urology · doi:10.1111/j.1464-410x.2010.09470.x · Cited by 121
Self-citationMouse models of prostate cancer: picking the best model for the question
Grabowska, M. M., DeGraff, D. J., Yu, X., Jin, R. J., Chen, Z., Borowsky, A. D., & Matusik, R. J. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9487-8 · Cited by 119
Considerations When Analyzing the Methylation Status of PTEN Tumor Suppressor Gene
Zysman, M., Chapman, W. B., & Bapat, B. V. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64902-4 · Cited by 110
Marques, R. B., Aghai, A., de Ridder, C. M. A., Stuurman, D. C., Hoeben, S. A. H., Boer, A., Ellston, R. P. A., Barry, S. T., Davies, B. R., Trapman, J., et al. (2014) · European Urology · doi:10.1016/j.eururo.2014.08.053 · Cited by 108
Verhagen, P. C. M. S., van Duijn, P. W., Hermans, K., Looijenga, L. H. J., van Gurp, R., Stoop, H., van der Kwast, T., & Trapman, J. (2006) · The Journal of Pathology · doi:10.1002/path.1929 · Cited by 108
Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer
on behalf of the Transatlantic Prostate Group, Cuzick, J. M., Yang, Z., Fisher, G., Tikishvili, E., Stone, S., Lanchbury, J. S. S., Camacho, N., Merson, S., Brewer, D. S., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.248 · Cited by 105
The functions of tumor suppressor PTEN in innate and adaptive immunity
Chen, L., & Guo, D. (2017) · Cellular and Molecular Immunology · doi:10.1038/cmi.2017.30 · Cited by 103
PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer
Mithal, P., Allott, E. H., Gerber, L., Reid, J., Welbourn, W., Tikishvili, E., Park, J., Younus, A., Sangale, Z., Lanchbury, J. S. S., et al. (2014) · International Journal of Urology · doi:10.1111/iju.12571 · Cited by 98
Armstrong, A. J., Halabi, S., Healy, P. N., Alumkal, J. J., Winters, C., Kephart, J. J. G., Bitting, R. L., Hobbs, C. A., Soleau, C., Beer, T. M., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.02.030 · Cited by 98
Lotan, T. L., Wei, W., Ludkovski, O., Morais, C. L., Guedes, L. B., Jamaspishvili, T., Lopez, K., Hawley, S. T., Feng, Z., Fazli, L., et al. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.88 · Cited by 97
Self-citationVulnerabilities of PTEN – TP53 -Deficient Prostate Cancers to Compound PARP–PI3K Inhibition
González‐Billalabeitia, E., Seitzer, N., Song, S. J., Song, M. S., Patnaik, A., Liu, X., Epping, M. T., Papa, A., Hobbs, R. M., Chen, M., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0230 · Cited by 96
Punnoose, E. A., Ferraldeschi, R., Szafer‐Glusman, E., Tucker, E., Mohan, S., Flohr, P., Riisnaes, R., Miranda, S., Figueiredo, I., Rodrigues, D. N., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.332 · Cited by 95
Heterogeneous Methylation and Deletion Patterns of the INK4a/ARF Locus Within Prostate Carcinomas
Konishi, N., Nakamura, M., Kishi, M., Nishimine, M., Ishida, E., & Shimada, K. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62547-3 · Cited by 94
Lotan, T. L., Heumann, A., Rico, S. D., Hicks, J. L., Lecksell, K., Koop, C., Sauter, G., Schlomm, T., & Simon, R. (2017) · Oncotarget · doi:10.18632/oncotarget.19217 · Cited by 92
Self-citationMassard, C., Chi, K. N., Castellano, D., Bono, J. S. D., Gravis, G., Dirix, L. Y., Machiels, J., Mita, A. C., Mellado, B., Turri, S., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.024 · Cited by 91
Tosoian, J. J., Almutairi, F., Morais, C. L., Glavaris, S. A., Hicks, J. L., Sundi, D., Humphreys, E. B., Han, M., Marzo, A. M. D., Ross, A. E., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.07.026 · Cited by 89
Self-citationLow-risk Prostate Cancer: Identification, Management, and Outcomes
Moschini, M., Carroll, P. R., Eggener, S. E., Epstein, J. I., Graefen, M., Montironi, R., & Parker, C. C. (2017) · European Urology · doi:10.1016/j.eururo.2017.03.009 · Cited by 85
Ma, T. M., Tosoian, J. J., Schaeffer, E. M., Landis, P., Wolf, S., Macura, K. J., Epstein, J. I., Mamawala, M. K., & Carter, H. B. (2016) · European Urology · doi:10.1016/j.eururo.2016.05.021 · Cited by 80
Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer
Krohn, A., Freudenthaler, F., Harasimowicz, S., Kluth, M., Fuchs, S., Burkhardt, L., Stahl, P. R., Tsourlakis, M. C., Bauer, M., Tennstedt, P., et al. (2014) · Modern Pathology · doi:10.1038/modpathol.2014.70 · Cited by 79
Mutational Landscape of Aggressive Prostate Tumors in African American Men
Lindquist, K. J., Paris, P. L., Hoffmann, T. J., Cardin, N. J., Kazma, R., Mefford, J., Simko, J. P., Ngo, V., Chen, Y., Levin, A. M., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1787 · Cited by 77
Choucair, K., Ejdelman, J., Brimo, F., Aprikian, A. G., Chevalier, S., & Lapointe, J. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-543 · Cited by 76
Lotan, T. L., Wei, W., Morais, C. L., Hawley, S. T., Fazli, L., Hurtado‐Coll, A., Troyer, D. A., McKenney, J. K., Simko, J. P., Carroll, P. R., et al. (2015) · European Urology Focus · doi:10.1016/j.euf.2015.07.005 · Cited by 76
Self-citationGümüşkaya, B., Gürel, B., Fedor, H. L., Tan, H.-L., Weier, C. A., Hicks, J. L., Haffner, M. C., Lotan, T. L., & Marzo, A. M. D. (2013) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2013.8 · Cited by 72
Self-citationA Robust Immunohistochemical Assay for Detecting PTEN Expression in Human Tumors
Sangale, Z., Prass, C. E., Carlson, A., Tikishvili, E., DeGrado, J., Lanchbury, J. S. S., & Stone, S. (2010) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0b013e3181f1da13 · Cited by 69
Troyer, D. A., Jamaspishvili, T., Wei, W., Feng, Z., Good, J. L., Hawley, S., Fazli, L., McKenney, J. K., Simko, J. P., Hurtado‐Coll, A., et al. (2015) · The Prostate · doi:10.1002/pros.23003 · Cited by 69
Self-citationA phase 2 clinical trial of everolimus plus bicalutamide for castration‐resistant prostate cancer
Chow, H., Ghosh, P., White, R. D., Evans, C. P., Dall’Era, M., Yap, S. A., Li, Y., Beckett, L. A., Lara, P. N., & Pan, C.-X. (2016) · Cancer · doi:10.1002/cncr.29927 · Cited by 66
Yoshimoto, M., Ludkovski, O., DeGrace, D., Williams, J. L., Evans, A. J., Sircar, K., Bismar, T. A., Nuin, P. A. S., & Squire, J. A. (2011) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20939 · Cited by 64
Self-citationCopy number variations in urine cell free DNA as biomarkers in advanced prostate cancer
Xia, Y. F., Huang, C., Dittmar, R. L., Du, M., Wang, Y., Liu, H., Shenoy, N. K., Wang, L., & Kohli, M. (2016) · Oncotarget · doi:10.18632/oncotarget.9027 · Cited by 62
A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53
Kim, J., Roh, M., Doubinskaia, I., Algarroba, G. N., Eltoum, I.-E. A., & Abdulkadir, S. A. (2011) · Oncogene · doi:10.1038/onc.2011.236 · Cited by 61
Lokman, U., Erickson, A. M., Vasarainen, H., Rannikko, A. S., & Mirtti, T. K. (2017) · European Urology Focus · doi:10.1016/j.euf.2017.03.004 · Cited by 61
Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration‐resistant prostate cancer
Bismar, T. A., Yoshimoto, M., Duan, Q., Liu, S., Sircar, K., & Squire, J. A. (2012) · Histopathology · doi:10.1111/j.1365-2559.2011.04116.x · Cited by 60
Self-citationvan de Ven, A. L., Tangutoori, S., Baldwin, P., Qiao, J., Gharagouzloo, C. A., Seitzer, N., Clohessy, J. G., Makrigiorgos, G. M., Cormack, R. A., Pandolfi, P. P., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0740 · Cited by 59
Wei, X. X., Hsieh, A. C., Kim, W. K., Friedlander, T. W., Lin, A., Louttit, M., & Ryan, C. J. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0432 · Cited by 56
Premalignancy in Prostate Cancer: Rethinking What We Know
Marzo, A. M. D., Haffner, M. C., Lotan, T. L., Yegnasubramanian, S., & Nelson, W. G. (2016) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-15-0431 · Cited by 53
Self-citationBono, J. S. D., Giorgi, U. D., Massard, C., Sergio Bracarda, A., Rodrigues, D. N., Kocák, I., Pous, A. F., Arija, J. Á. A., Shih, K. C., Rădăvoi, G. D., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw372.02 · Cited by 53
Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer
Reid, A. H. M., Attard, G., Brewer, D. S., Miranda, S., Riisnaes, R., Clark, J., Hylands, L., Merson, S., Vergis, R., Jameson, C., et al. (2012) · Modern Pathology · doi:10.1038/modpathol.2011.207 · Cited by 51
Oncolysis of Prostate Cancers Induced by Vesicular Stomatitis Virus in PTEN Knockout Mice
Moussavi, M., Fazli, L., Tearle, H., Guo, Y., Cox, M., Bell, J. C., Ong, C. J., Jia, W. W.-G., & Rennie, P. S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2377 · Cited by 45
Couto, S. S., Cao, M., Duarte, P. C. X., Banach-Petrosky, W. A., Wang, S., Romanienko, P. J., Wu, H., Cardiff, R. D., Abate-Shen, C. T., & Cunha, G. R. (2009) · Differentiation · doi:10.1016/j.diff.2008.09.010 · Cited by 39
Picanço-Albuquerque, C. G., Morais, C. L., Carvalho, F. L. F., Peskoe, S. B., Hicks, J. L., Ludkovski, O., Vidotto, T., Fedor, H. L., Humphreys, E. B., Han, M., et al. (2016) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-016-1904-2 · Cited by 38
Self-citationAnalysis of circulating regulatory T cells (CD4+CD25+CD127−) after cryosurgery in prostate cancer
Si, T.-G., Wang, J.-P., & Guo, Z. (2013) · Asian Journal of Andrology · doi:10.1038/aja.2013.22 · Cited by 26
Whang, Y. E., Wu, X., & Sawyers, C. L. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.11.859 · Cited by 24
Ibeawuchi, C., Schmidt, H., Voß, R., Titze, U., Abbas, M., Neumann, J., Eltze, E., Hoogland, A. M., Jenster, G. W., Brandt, B., et al. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16023856 · Cited by 20
Immunotherapy for Prostate Cancer: An Emerging Treatment Modality
Drake, C. G. (2010) · Urologic Clinics of North America · doi:10.1016/j.ucl.2009.11.001 · Cited by 13
Cited by
Yi, J., Zhu, J., Wu, J., Thompson, C. B., & Jiang, X. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2017152117 · Cited by 974
Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches
Sekhoacha, M., Riet, K., Motloung, P., Gumenku, L., Adegoke, A., & Mashele, S. (2022) · Molecules · doi:10.3390/molecules27175730 · Cited by 904
Tewari, D., Patni, P., Bishayee, A., Sah, A. N., & Bishayee, A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.008 · Cited by 642
The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling
Shorning, B. Y., Dass, M. S., Smalley, M. J., & Pearson, H. B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124507 · Cited by 616
Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention
Butler, L. M., Perone, Y., Dehairs, J., Lupien, L. E., de Laat, V., Talebi, A., Loda, M., Kinlaw, W. B., & Swinnen, J. V. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.013 · Cited by 589
Metadata
- Authors
- Jamaspishvili, T., Berman, D. M., Ross, A. E., Scher, H. I., De Marzo, A. M., Squire, J. A., & Lotan, T. L.
- Venue
- Nature Reviews Urology
- Published
- 2018-02-20
- Volume
- 15
- Issue
- 4
- Pages
- 222-234
- ISSN
- 1759-4812 (ISSN-L)
- 1759-4820
- OpenAlex
- W2788783025
- Cited by
- 651
- References
- 137
- FWCI
- 14.01
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.